Disease · MONDO_0005348

keloid

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. keloid. Diseases, record MONDO_0005348. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005348

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: keloid; Open Targets
Open Targets ID: MONDO_0005348; Open Targets
Other names: keloids; Open Targets
MeSH: D007627; MeSH
NCI Thesaurus: C3145; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 34 drugs, from ClinicalTrials.gov; Open Targets

Drugs34

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 3	ClinicalTrials.gov	3	3	2	Drugs and targets
ERGOCALCIFEROL	CHEMBL1536	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Phase 2	ClinicalTrials.gov	15	15	14	Drugs and targets
TRIAMCINOLONE	CHEMBL1451	Small molecule	Phase 2	ClinicalTrials.gov	4	4	3	Drugs and targets
METHYLPREDNISOLONE ACETATE	CHEMBL1364144	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
ONABOTULINUMTOXINA	CHEMBL1201574		Phase 2	ClinicalTrials.gov	2	2	0	Drugs and targets
TRIAMCINOLONE HEXACETONIDE	CHEMBL1200878	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
BETAMETHASONE DIPROPIONATE	CHEMBL1200384	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
BETAMETHASONE SODIUM PHOSPHATE	CHEMBL1200762	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 34

See all 34 drugs

Targets29

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	13	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	3	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 3	https://conductscience.org/library/genes/6616	Drugs and targets
VDR	Vitamin D3 receptor	2	Vitamin D receptor agonist	Phase 3	https://conductscience.org/library/genes/7421	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	1	Type-1 angiotensin II receptor antagonist	Phase 1/2	https://conductscience.org/library/genes/185	Drugs and targets
BMX	TEC family kinase	1	TEC family kinase inhibitor	Phase 2	https://conductscience.org/library/genes/660	Drugs and targets
BRAF	Serine/threonine-protein kinase B-raf	1	Serine/threonine-protein kinase B-raf inhibitor	Phase 2	https://conductscience.org/library/genes/673	Drugs and targets
BTK	TEC family kinase	1	TEC family kinase inhibitor	Phase 2	https://conductscience.org/library/genes/695	Drugs and targets
CACNA1C	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1F	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Unknown	https://conductscience.org/library/genes/778	Drugs and targets

1 to 10 of 29

See all 29 targets

Trials31

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02996097	Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids	Not applicable	30	2019-04-25	Keloid	TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT04049552	RAPA-Keloid Study of Keloid Regression	Early phase 1	4	2020-12-28	Keloid	SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT07596628	siRNA Microneedle Patches for Ear Keloid Post-Surgical Scars	Phase 2	158		Keloid of Ear Lobe	TRIAMCINOLONE	Its record names the disease	ClinicalTrials.gov
NCT07201766	The Efficacy of Intralesional Bleomycin as Compared to 5-Flourouracil (5-FU) and Triamcinolone Acetonide (TAC) for the Treatment of Keloids: A Randomized Control Trial.	Not applicable	104		Keloids Scars	BLEOMYCIN, FLUOROURACIL, TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT07606391	Polidocanol 1% and Steroid in Keloids and Hypertrophic Scars	Not applicable	90		Keloid and Hypertrophic Scars	POLIDOCANOL, TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT07531056	Comparison Of Effectiveness Of Intralesional Injectioms Of 5 Flourouracil Alone Verses Its Cpmbination With Cryotherapy In The Treatment Of Keloids	Early phase 1	88		Keloids	FLUOROURACIL	Its record names the disease	ClinicalTrials.gov
NCT04812626	Intralesional Triamcinolone Acetonide and Its Combination With 5-fluorouracil in Keloids and Hypertrophic Scars	Not applicable	66		Scar Keloid	FLUOROURACIL, TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT01425216	Sorafenib for Patients With Extensive Keloids	Phase 2	60		Keloids	SORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT07420166	Comparison of Intralesional Triamcinolone Acetonide Treatment With Intralesional Verapamil Hydrochloride in Keloids	Not applicable	60		Keloid	TRIAMCINOLONE ACETONIDE, VERAPAMIL HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT07013240	Botulinum Toxin Injection After Sternotomies to Improve Scar Aspect and Impact	Phase 3	50		Sternotomy Closure,Open Heart Surgery	BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov

1 to 10 of 31

See all 31 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
RAPA Intervention vs Placebo: deaths from any cause	0 of 3	0 of 3	6	NCT04049552	Trial comparisons
RAPA Intervention vs Placebo: serious adverse events	0 of 3	0 of 3	6	NCT04049552	Trial comparisons

Papers from its trials11

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29799555	RESULT	1	PubMed
29499740	RESULT	1	PubMed
29467010	RESULT	1	PubMed
28316259	RESULT	1	PubMed
19295939	RESULT	1	PubMed
11807470	RESULT	1	PubMed
2682703	RESULT	1	PubMed
41039790	DERIVED	1	PubMed
40135774	DERIVED	1	PubMed
38167064	DERIVED	1	PubMed

1 to 10 of 11

See all 11 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005348

GET https://conductscience.org/api/diseases/v1/MONDO_0005348/drugs?page=2

API reference For AI assistants